S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$15.00
-0.19 (-1.25 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.68
Now: $15.00
$15.43
50-Day Range
$12.93
MA: $13.87
$15.19
52-Week Range
$10.63
Now: $15.00
$24.46
Volume60,050 shs
Average Volume157,696 shs
Market Capitalization$493.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals logo

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

300th out of 1,926 stocks

Pharmaceutical Preparations Industry

153rd out of 773 stocks

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464
Employees68

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 million
Book Value$4.84 per share

Profitability

Net Income$-50,420,000.00

Miscellaneous

Market Cap$493.83 million
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable
$15.00
-0.19 (-1.25 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

How has Crinetics Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX stock has decreased by 3.2% and is now trading at $15.00.
View which stocks have been most impacted by COVID-19
.

Is Crinetics Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Crinetics Pharmaceuticals?

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Crinetics Pharmaceuticals' CEO?

1,448 employees have rated Crinetics Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Crinetics Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings results on Wednesday, November, 11th. The company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.03.
View Crinetics Pharmaceuticals' earnings history
.

What price target have analysts set for CRNX?

3 equities research analysts have issued 12-month price objectives for Crinetics Pharmaceuticals' stock. Their forecasts range from $30.00 to $42.00. On average, they anticipate Crinetics Pharmaceuticals' stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 140.0% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 58, Pay $715.39k)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 41, Pay $450k)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 57, Pay $571.97k)
  • Dr. Yun-Fei Zhu, Founder & VP of Chemistry (Age 57)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 54)
  • Ms. Adriana Cabre, VP of HR
  • Dr. Ajay Madan DABT, Ph.D., D.A.B.T., Chief Devel. Officer (Age 52)
  • Mr. Peter Trainer BSc, MBChB, M.D., FRCP, VP of Clinical Endocrinology

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $15.00.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $493.83 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 68 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.